Compare Incyte Corporation (INCY) vs Spotify Technology (SPOT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Spotify Technology — how do they compare? Incyte Corporation trades at $117.62 (market cap $23.11B), while Spotify Technology trades at $490.01 (market cap $101.23B). The key difference: Spotify Technology is far larger — about 4.4× Incyte Corporation's market cap, and Incyte Corporation is trading nearer its 52-week high, Spotify Technology nearer its low. Which is the better fit depends on your goals.
| INCY | SPOT | |
|---|---|---|
Market Cap | $23.11B | $101.23B |
Sector | Health | Media |
52-Week High | $118.52 | $738.53 |
52-Week Low | $67.38 | $412.75 |
Enterprise Value | $19.13B | $91.81B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
Spotify (SPOT) trades at $493.49, up 3.21% today, showing strong momentum after recent earnings beats. The stock faces technical resistance near $498 with bearish moving average signals. Fundamentally, the company demonstrates impressive growth with revenue reaching $17.19B in 2025 and net income surging to $2.21B, representing a 12.87% margin. Recent AI integration initiatives and expanded family account features highlight ongoing innovation.
Wall Street maintains a bullish stance with 61.5% buy ratings and a $617 consensus target, representing 25% upside potential. However, elevated valuation multiples (P/E 32.6, P/S 5.0) and competitive pressures from streaming rivals present near-term risks. The Q2 2026 earnings report will be crucial for validating the current growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Spotify Technology
Spotify Technology S.A. provides music streaming services. The Company offers commercial-free music and ad-supported services to subscribers. Spotify Technology serves clients worldwide.
Read more on SPOT →
